Nexalin Technology receives Nasdaq bid price deficiency notice [Seeking Alpha]
Nexalin Technology Receives Nasdaq Listing Status Notification
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4